TB R&D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB

Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis. Cell Host Microbe. 2011 Nov 17;10(5):475-85.

This week’s article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages. The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria. Key points from the article are:

  • Data from experiments using TK inhibitors and cell lines from knockout animals show that there is a role for specific TKs in Mtb and related bacteria’s processes for entry and intracellular survival. Also, it appears multiple kinases mediate intracellular survival within macrophages.
  • Imatinib, an inhibitor of some TKs and used in cancer therapy, was shown to reduce bacterial loads in macrophages and mice infected with Mtb or M. marinum. Imatinib also seems to have synergy with drugs like rifampicin and rifabutin.
  • There has been low toxicity reported in patients although there is some reported toxicity in patients taking imatinib with long-term exposure. This may suggest looking at imatinib as a therapeutic against active TB or reactivated TB. The benefit of targeting the host with imatinib is that the bacteria would need to make a major adaptation to develop resistance and also could confer some protection to current first-line drugs by reducing the bacterial burden below the spontaneous mutation frequency.

Additional TB R&D News:

SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time

Hyderabad scientists discover TB bacteria killer

Eli Lilly and Company Provides IDRI with Additional Funding for Identification of New Tuberculosis Therapies

Tuberculosis – Novel Tools And Coordination Required

Webcams Connect TB Patients to Public Clinic for Treatment Compliance

More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...